ADENOSINE injection, solution

Maa: Yhdysvallat

Kieli: englanti

Lähde: NLM (National Library of Medicine)

Aktiivinen ainesosa:

ADENOSINE (UNII: K72T3FS567) (ADENOSINE - UNII:K72T3FS567)

Saatavilla:

HF Acquisition Co LLC, DBA HealthFirst

Antoreitti:

INTRAVENOUS

Prescription tyyppi:

PRESCRIPTION DRUG

Käyttöaiheet:

Intravenous adenosine injection is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine injection administration. It is important to be sure the adenosine injection solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION). Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. Intravenous adenosine injection is contraindicated in: Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker). Sinus node disease, such as sick sinus syndrome or

Tuoteyhteenveto:

Adenosine Injection, USP is supplied as a sterile, non-pyrogenic solution in normal saline. NDC 51662-1632-1 ADENOSINE INJECTION, USP 6mg/2mL (3mg/mL) 2mL SINGLE USE VIAL, 3 mg/ml HF Acquisition Co LLC, DBA HealthFirst 11629 49th Pl W. Mukilteo, WA 98275 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. DO NOT REFRIGERATE as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear and particle free at the time of use. CONTAINS NO PRESERVATIVES. DISCARD UNUSED PORTION. This container closure is not made with natural rubber latex.

Valtuutuksen tilan:

Abbreviated New Drug Application

Valmisteyhteenveto

ADENOSINE- ADENOSINE INJECTION, SOLUTION
HF ACQUISITION CO LLC, DBA HEALTHFIRST
----------
ADENOSINE INJECTION, USP 6MG/2ML (3MG/ML) 2ML VIAL
SPL UNCLASSIFIED
Rx only
FOR RAPID BOLUS INTRAVENOUS USE
DESCRIPTION
Adenosine is an endogenous nucleoside occurring in all cells of the
body. It is chemically
6-amino-9-ß-D-ribofuranosyl-9-H-purine and has the following
structural formula:
Adenosine is a white crystalline powder. It is soluble in water and
practically insoluble in
alcohol. Solubility increases by warming and lowering the pH.
Adenosine is not chemically
related to other antiarrhythmic drugs. Adenosine Injection is a
sterile, nonpyrogenic
solution for rapid bolus intravenous injection. Each mL contains 3 mg
adenosine and 9
mg sodium chloride in water for injection. The pH of the solution is
between 4.5 and 7.5.
CLINICAL PHARMACOLOGY
Mechanism of Action
Adenosine slows conduction time through the A-V node, can interrupt
the re-entry
pathways through the A-V node, and can restore normal sinus rhythm in
patients with
paroxysmal supraventricular tachycardia (PSVT), including PSVT
associated with Wolff-
Parkinson-White Syndrome.
Adenosine is antagonized competitively by methylxanthines such as
caffeine and
theophylline, and potentiated by blockers of nucleoside transport such
as dipyridamole.
Adenosine is not blocked by atropine.
Hemodynamics
The intravenous bolus dose of 6 or 12 mg adenosine injection usually
has no systemic
hemodynamic effects. When larger doses are given by infusion,
adenosine decreases
blood pressure by decreasing peripheral resistance.
Pharmacokinetics
Intravenously administered adenosine is rapidly cleared from the
circulation via cellular
uptake, primarily by erythrocytes and vascular endothelial cells. This
process involves a
specific transmembrane nucleoside carrier system that is reversible,
nonconcentrative,
and bidirectionally symmetrical. Intracellular adenosine is rapidly
metabolized either via
phosphorylation to adenosine monophosphate by adenosine kinase, or via
deamination
to in